Table 3 Traditional and modified myeloablative (MA) regimens
MAC | Drug | Dose(total) | Schedule(d) | Donor type |
|---|---|---|---|---|
Traditional | ||||
Cy/TBI | Cy | 120 mg/kg | − 6, − 5 | Allo-HSCT |
f-TBI | 12 ~ 14 Gy | − 3 ~ − 1 | ||
Bu/Cy | Bu | 16 mg/kg(po)or 12.8/kg(iv) | −7 ~ − 4 | Allo-HSCT |
Cy | 120 mg/kg | − 3, − 2 | ||
Modified (PUPH) | ||||
mBuCy | Hu | 80 mg/kg, divided in twice | − 10 | HLA-matched sibling HSCT |
Ara-C | 2 g/m2 | − 9 | ||
Bu | 9.6 mg/kg(iv) | − 8 ~ − 6 | ||
Cy | 3.6 g/m2 | − 5, − 4 | ||
MeCCNU | 250 mg/m2(po) | − 3 | ||
mCy/TBI | Single TBI | 770 cGy | − 6 | HLA-matched sibling HSCT |
Cy | 3.6 g/m2 | − 5, -4 | ||
MeCCNU | 250 mg/m2 | − 3 | ||
mBuCy+ATG | Ara-C | 4~ 8 g/m2 | − 10, − 9 | URD, CBT, HID-HSCT |
Bu | 9.6 mg/kg(iv) | − 8 ~ − 6 | ||
Cy | 3.6 g/m2 | − 5, − 4 | ||
ATG | 10 mg/kg | −5 ~ − 2 | ||
Or ATG-F | 40 mg/kg | −5 ~ − 2 | ||
mCy/TBI + ATG | TBI | 770 cGy | − 6 | URD-HSCT, HID-HSCT |
Cy | 3.6 g/m2 | − 5, − 4 | ||
MeCCNU | 250 mg/m2 | −3 | ||
ATG | 10 mg/kg | −5 ~ − 2 | ||
Or ATG-F | 40 mg/kg | −5 ~ − 2 | ||